Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | GLA | P06280 | 1/20 | 0.62 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9331793 | 0.86 | L3MBTL1 (0.59) | LMNAKDM4ESMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL10742425 | 0.86 | LMNA (0.60) | LMNAKDM4ESMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL29502958 | 0.85 | KDM4E (0.73) | KDM4ESMN1; SMN2ALDH1A1L3MBTL1POLB | |
| SCHEMBL8414408 | 0.85 | L3MBTL1 (0.61) | KDM4ESMN1; SMN2ALDH1A1L3MBTL1POLB | |
| SCHEMBL341639 | 0.85 | KDM4E (0.73) | KDM4ESMN1; SMN2ALDH1A1L3MBTL1POLB | |
| SCHEMBL11100909 | 0.84 | HTT (0.72) | LMNAKDM4ESMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL10966260 | 0.84 | LMNA (0.62) | LMNAKDM4ESMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL9979663 | 0.84 | LMNA (0.62) | LMNAKDM4ESMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL1280991 | 0.82 | POLB (0.64) | LMNAKDM4ESMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL7823764 | 0.82 | L3MBTL1 (0.64) | KDM4ESMN1; SMN2ALDH1A1L3MBTL1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11498926-B2 | Tricyclic heterocycles as BET protein inhibitors | INCYTE CORPORATION (US) | 2022-11-15 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| CN-110179777-B | Pharmaceutical compositions comprising nitroxyl donors | 卡尔迪奥克斯尔制药公司 | 2022-07-15 | — | — | CN | disclosed |
| US-11304924-B2 | Pharmaceutical compositions comprising nitroxyl donors | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2022-04-19 | — | — | US | disclosed |
| EP-3581576-B1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS FOR USE IN THE TREATMENT OF A PROLIFERATIVE DISEASE IN COMBINATION WITH A JANUS KINASE INHIBITOR | INCYTE HOLDINGS CORP (US) | 2022-01-26 | — | — | EP | disclosed |
| EP-3427728-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NITROXYL DONORS | CARDIOXYL PHARMACEUTICALS INC (US) | 2021-07-07 | — | — | EP | disclosed |
| US-20210188872-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORTION | 2021-06-24 | — | — | US | disclosed |
| US-10919912-B2 | Tricyclic heterocycles as BET protein inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2021-02-16 | — | — | US | disclosed |
| US-20200339570-A1 | BICYCLIC DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2020-10-29 | — | — | US | disclosed |
| CN-111518063-A | Method for preparing benzofuran from furan by one-step method | 中国科学技术大学 | 2020-08-11 | — | — | CN | disclosed |
| WO-2009085256-A1 | ANTI-HIV COMPOUNDS | PANACOS PHARMACEUTICALS, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| WO-2009085256-A1 | ANTI-HIV COMPOUNDS | PANACOS PHARMACEUTICALS, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| US-7335466-B2 | Silver salt photothermographic dry imaging material, image recording method and image forming method for the same | KONICA MINOLTA HOLDINGS, INC. (JP) | 2008-02-26 | — | — | US | disclosed |
| US-7335466-B2 | Silver salt photothermographic dry imaging material, image recording method and image forming method for the same | KONICA MINOLTA HOLDINGS, INC. (JP) | 2008-02-26 | — | — | US | disclosed |
| EP-0025109-B1 | 1-BENZOXEPIN-5(2H)-ONE DERIVATIVES AND THEIR SALTS, AND PROCESSES FOR THEIR PREPARATION | Kali-Chemie Pharma GmbH (DE) | 1985-05-15 | — | — | EP | disclosed |
| EP-0074121-B1 | 2,3,4,5-TETRAHYDRO-1-BENZOXEPINE-3,5-DIONE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | Kali-Chemie Pharma GmbH (DE) | 1985-04-10 | — | — | EP | disclosed |
| EP-0074121-A1 | 2,3,4,5-Tetrahydro-1-benzoxepine-3,5-dione derivatives and process for their preparation | Kali-Chemie Pharma GmbH (DE) | 1983-03-16 | — | — | EP | disclosed |
| US-4320061-A | ANTISPASMODIC AGENTS | KALI-CHEMIE PHARMA GMBH (DE) | 1982-03-16 | — | — | US | disclosed |
| US-4279905-A | GASTROINTESTINAL DISORDERS | KALI-CHEMIE PHARMA GMBH (DE) | 1981-07-21 | — | — | US | disclosed |
| EP-0025109-A2 | 1-Benzoxepin-5(2H)-one derivatives and their salts, and processes for their preparation | Kali-Chemie Pharma GmbH (DE) | 1981-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210188872-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | BRD1, BRD3, BRD2 | LMNA 3201/4885KDM4E 1447/4885SMN1; SMN2 4578/4885 |
| US-20200339570-A1 | BICYCLIC DERIVATIVES | CCNY, BICRA, UQCRB | LMNA 68/4885KDM4E 1613/4885SMN1; SMN2 3883/4885 |
| US-11498926-B2 | Tricyclic heterocycles as BET protein inhibitors | BRD1, BRD3, BRD2 | LMNA 3201/4885KDM4E 1447/4885SMN1; SMN2 4578/4885 |
| US-11304924-B2 | Pharmaceutical compositions comprising nitroxyl donors | TNNT2, TNNI3, NQO1 | LMNA 3141/4885KDM4E 1476/4885SMN1; SMN2 793/4885 |
| US-10919912-B2 | Tricyclic heterocycles as BET protein inhibitors | BRD1, BRD3, BRD2 | LMNA 3201/4885KDM4E 1447/4885SMN1; SMN2 4578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.